ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• High-Dose Delivery: Integration And Performance

  High-viscosity therapies bring new delivery challenges. Explore how needle, syringe, and device design affect injection performance, reliability, and user experience.

• Solving The Silicone Challenge In Pre-Fillable Syringes

  Discover a technology platform that is revolutionizing the pre-fillable syringe market by solving the challenge of silicone sensitivity, ensuring stability for sensitive drugs.

• Pharmaceutical Nanotechnology: What To Know

  Here is what you need to know about the key advantages that pharmaceutical nanotechnology provides in improving drug efficacy and decreasing adverse reactions.

• Maintaining Drug Bioavailability And Masking Taste With Microencapsulation

  Several technologies are available for microencapsulating drugs. Finding the right CDMO to optimize a drug’s efficacy and manufacturing during formulation is integral to its clinical and commercial success.

• FAQs On The Revised EU GMP Annex 1: Volume 3

  The EU GMP Annex 1 revision, effective August 2023, requires a detailed Contamination Control Strategy. Learn how it impacts global manufacturers, RABS use, and personnel procedures.

• Advancing Chronic Care Through GLP‑1 Innovation

  GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

• A Robust Extractables Data Package Helps Drive Patient Safety

  Complex drug product formulations are more common, so it is imperative to have a deeper knowledge of extractables to understand risks associated with potential interactions between packaging and product.

• Nanosuspension Dosage Forms: Product Development & Scale Up

  For drug nanosuspensions, parameters like stabilizer concentration, drug loading, milling speed, milling time, bead diameter/density, and temperature are important formulation and process variables.

• Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

  A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

• CMO As Partners For ADC Process Development, Scale-Up, Optimization

  ADC programs can accelerate through clinical phases rapidly, making early preparation for commercial launch imperative. It's sensible to partner with a CMO with a strong biologics foundation.